These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28162293)

  • 1. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
    Leon LA; Antón-Aparicio LM
    Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
    León-Mateos L; Mosquera J; Antón Aparicio L
    Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
    Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
    J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of hypertension side effects induced by sunitinib.
    Aparicio-Gallego G; Afonso-Afonso FJ; León-Mateos L; Fírvida-Pérez JL; Vázquez-Estévez S; Lázaro-Quintela M; Ramos-Vázquez M; Fernández-Calvo O; Campos-Balea B; Antón-Aparicio LM
    Anticancer Drugs; 2011 Jan; 22(1):1-8. PubMed ID: 20938340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
    Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
    Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
    Griffioen AW; Mans LA; de Graaf AMA; Nowak-Sliwinska P; de Hoog CLMM; de Jong TAM; Vyth-Dreese FA; van Beijnum JR; Bex A; Jonasch E
    Clin Cancer Res; 2012 Jul; 18(14):3961-3971. PubMed ID: 22573349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
    Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
    Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic therapy: concept to clinic.
    Young RJ; Reed MW
    Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine colitis treated with multitargeted tyrosine kinase inhibitors.
    Knod JL; Crawford K; Dusing M; Frischer JS
    J Surg Res; 2016 Feb; 200(2):501-7. PubMed ID: 26521099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
    Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
    Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
    Imano H; Kato R; Ijiri Y; Hayashi T
    Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.